» Authors » Lee Ponsky

Lee Ponsky

Explore the profile of Lee Ponsky including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 100
Citations 1519
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun H, Prunty M, Isali I, Mahran A, Ginsburg K, Markt S, et al.
Bladder Cancer . 2024 Jul; 7(4):439-447. PMID: 38993992
Background: Many variables may affect the cost of open radical cystectomy (RC) care, including surgical approach, diversion type, patient comorbidities, and postoperative complications. Objective: To determine factors associated with changes...
2.
Tan V, Correa R, Warner A, Ali M, Muacevic A, Ponsky L, et al.
Eur Urol Oncol . 2024 Jul; 7(6):1527-1534. PMID: 38987159
Background And Objective: Renal function preservation is particularly important following nonoperative treatment of localized renal cell carcinoma (RCC) since patients are often older with medical comorbidities. Our objective was to...
3.
Bukavina L, Ginwala R, Eltoukhi M, Sindhani M, Prunty M, Geynisman D, et al.
Cancer Res Commun . 2024 May; 4(6):1505-1516. PMID: 38747616
Significance: Our study highlights results that link the composition of the GM to the efficacy of NAC in MIBC. We discovered that patients with higher levels of Bacteroides experienced a...
4.
Motzer R, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al.
J Natl Compr Canc Netw . 2024 Feb; 22(1):4-16. PMID: 38394781
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic...
5.
Bukavina L, Davis L, Helstrom E, Magee D, Ponsky L, Uzzo R, et al.
Eur Urol Focus . 2024 Feb; 10(2):298-302. PMID: 38326120
Background And Objective: The rationale for oophorectomy during female cystectomy is not adequately supported. The co-occurrence and timing of bladder cancer (BC) and ovarian cancer (OC) in females harboring OC...
6.
Gharzai L, Jiang R, Jaworski E, Morales Rivera K, Dess R, Jackson W, et al.
NEJM Evid . 2024 Feb; 2(4):EVIDoa2200195. PMID: 38320030
BACKGROUND: The Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) working group identified metastasis-free survival as a valid surrogate end point for overall survival (OS) for patients with localized...
7.
Brant A, Lewicki P, Wu X, Sze C, Johnson J, Ponsky L, et al.
J Gen Intern Med . 2023 Dec; 39(8):1414-1422. PMID: 38148474
Background: The FDA issued a "black box" warning regarding risks of fluoroquinolones in 2008 with updates in 2011, 2013, and 2016. Objective: To examine antimicrobial use in hospital-treated UTIs from...
8.
Zhu A, Rhodes S, Dong W, Rose J, Cullen J, Miller D, et al.
JNCI Cancer Spectr . 2023 Oct; 7(6). PMID: 37796836
Background: Prior work assessing disparities in cancer outcomes has relied on regional socioeconomic metrics. These metrics average data across many individuals, resulting in a loss of granularity and confounding with...
9.
Midya A, Hiremath A, Huber J, Viswanathan V, Omil-Lima D, Mahran A, et al.
Front Oncol . 2023 Sep; 13:1166047. PMID: 37731630
Objective: The aim of this study was to quantify radiomic changes in prostate cancer (PCa) progression on serial MRI among patients on active surveillance (AS) and evaluate their association with...
10.
Edwins R, Pominville R, Ponsky L, Hannick J
Med Educ . 2023 Sep; 57(11):1127. PMID: 37721217
No abstract available.